Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Avalon Globocare Corp (ALBT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Avalon Globocare's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.2628 +0.0162    +6.57%
06/05 - Closed. Currency in USD ( Disclaimer )
After Hours
0.2534
-0.0094
-3.5769%
0:58:58 - Real-time Data
  • Volume: 52,970
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.2451 - 0.3100
Type:  Equity
Market:  United States
Avalon Globocare 0.2628 +0.0162 +6.57%

Avalon Globocare Company Profile

 
Read the Avalon Globocare Corp company profile to learn more about the business and the management team. View Avalon Globocare Corp facts about employee data, company products and services, and contact information.
IndustryHealthcare Providers & Services
SectorHealthcare
Employees

6

Equity Type

ORD

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Contact Information

Address 4400 Route 9 South Suite 3100
Freehold, 07728
United States
Phone 732 780 4400
Fax 732 780 5600

Top Executives

Name Age Since Title
Robert S. Langer 74 2019 Member of Scientific & Clinical Advisory Board
Yen-Michael S. Hsu - - Member of Scientific & Clinical Advisory Board
Wenchun Qu - - Member of Scientific & Clinical Advisory Board
Peihua Peggy Lu - - Member of Scientific & Clinical Advisory Board
Hongxing Liu - 2022 Member of Scientific and Clinical Advisory Board
Lourdes Felix 55 2023 Independent Director
Wenzhao Lu 64 2016 Chairman of the Board
William B. Stilley 55 2018 Independent Director
James L. Gajewski - 2018 Head of Scientific & Clinical Advisory Board
David K. Jin 55 2016 CEO, President & Director
Shahin Rafii - - Member of Scientific & Clinical Advisory Board
Tevi Troy 55 2018 Independent Director
Wilbert J. Tauzin 79 2017 Director
Xin Lin - - Member of Scientific & Clinical Advisory Board
Uwe. B Sleytr - 2020 Member of Scientific & Clinical Advisory Board
Steven Andrew Sanders 78 2018 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALBT Price Commentary

Write your thoughts about Avalon Globocare Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email